SPY389.63+0.17 0.04%
DIA312.42-0.01 0.00%
IXIC11,354.62-33.88 -0.30%

Opiant Pharmaceuticals Says To 'Disregard' Prior News Of $225M Licensing Agreement; Says Intial Release 'Contains Incorrect Information

We are advised by Opiant Pharmaceuticals that journalists and other readers should disregard the news release, Opiant Pharmaceuticals and Hikma announce exclusive $225 million commercialisation and license agreement for

Benzinga · 04/29/2022 11:33

We are advised by Opiant Pharmaceuticals that journalists and other readers should disregard the news release, Opiant Pharmaceuticals and Hikma announce exclusive $225 million commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK, issued 29-Apr-2022 over PR Newswire. This release contains incorrect information.